Growth in its U.S. ultrasound contrast business contributed to a 7% increase in revenue for Lantheus Medical Imaging in its second quarter.
For the period (end-June 30), Lantheus turned in worldwide revenue of $75.6 million, up from $70.6 million a year ago. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) climbed from $6.5 million a year ago to $16.3 million. The firm reported a net loss of $1.6 million, an improvement over the net loss of $14.5 million in the second quarter of 2013.
Jeffrey Bailey, Lantheus' president and CEO, noted that revenues from the company's Definity ultrasound contrast agent again grew sequentially, thanks to continued growth in the U.S. ultrasound contrast market and the efforts of the company's sales force.
